Pabinger-Fasching I - Search Results

1

[Blood coagulation disorders in leukemia].

Pabinger-Fasching I. Pabinger-Fasching I. Wien Med Wochenschr. 1991;141(9-10):213-6. Wien Med Wochenschr. 1991. PMID: 1949847 Review. German.

2

[Monitoring blood coagulation].

Pabinger-Fasching I. Pabinger-Fasching I. Wien Med Wochenschr. 1999;149(2-4):70-1. Wien Med Wochenschr. 1999. PMID: 10378328 German.

3

Hemostatic and fibrinolytic parameters in patients with acute myeloid leukemia: activation of blood coagulation, fibrinolysis and unspecific proteolysis.

Speiser W, Pabinger-Fasching I, Kyrle PA, Kapiotis S, Kottas-Heldenberg A, Bettelheim P, Lechner K. Speiser W, et al. Blut. 1990 Nov;61(5):298-302. doi: 10.1007/BF01732881. Blut. 1990. PMID: 2271776

4

[Prevention of venous thromboembolism in musculoskeletal surgery].

Pabinger-Fasching I, Eichinger-Hasenauer S, Grohs J, Hochreiter J, Kastner N, Korninger HC, Kozek-Langenecker S, Marlovits S, Niessner H, Rachbauer F, Ritschl P, Wurnig C, Windhager R. Pabinger-Fasching I, et al. Wien Klin Wochenschr. 2014 May;126(9-10):298-310. doi: 10.1007/s00508-014-0509-5. Epub 2014 May 14. Wien Klin Wochenschr. 2014. PMID: 24825594 German.

5

Disseminated intravascular coagulation and decrease in fibrinogen levels induced by vincristine/prednisolone therapy of lymphoid blast crisis of chronic myeloid leukemia.

Sunder-Plassmann G, Speiser W, Korninger C, Stain M, Bettelheim P, Pabinger-Fasching I, Lechner K. Sunder-Plassmann G, et al. Ann Hematol. 1991 May;62(5):169-73. doi: 10.1007/BF01703143. Ann Hematol. 1991. PMID: 2049463

6

[Periprocedual management of vitamin K antagonist's with low molecular weight heparins during invasive procedures--Consensus of experts].

Watzke H, Metzler H, Weltermann A, Marschang P, Brodmann M, Lang W, Pabinger-Fasching I, Mahla E, Kozek-Langenecker S, Guschmann M, Huber K. Watzke H, et al. Wien Klin Wochenschr. 2013 Jul;125(13-14):412-20. doi: 10.1007/s00508-013-0390-7. Wien Klin Wochenschr. 2013. PMID: 23797530 German.

7

Symptomatic hereditary type-II protein C deficiency caused by a missense mutation in exon IX of the protein C gene (Gly381 to Ser).

Wittmann E, Walter J, Pabinger-Fasching I, Watzke HH. Wittmann E, et al. Ann Hematol. 1994 May;68(5):255-9. doi: 10.1007/BF01737427. Ann Hematol. 1994. PMID: 8018768

8

[Thromboembolism--genetic and acquired risk factors].

Pabinger-Fasching I. Pabinger-Fasching I. Acta Med Austriaca. 1999;26(2):37-40. Acta Med Austriaca. 1999. PMID: 10478276 Review. German.

9

Protein C- and coagulation factor levels during the initial phase of oral anticoagulant therapy (low dose regimen) in a patient with heterozygous protein C deficiency.

Pabinger-Fasching I, Lechner K, Niessner H, Korninger C, Kyrle PA. Pabinger-Fasching I, et al. Thromb Res. 1987 Sep 15;47(6):705-8. doi: 10.1016/0049-3848(87)90110-1. Thromb Res. 1987. PMID: 3686485 No abstract available.

10

High levels of plasma protein C in nephrotic syndrome.

Pabinger-Fasching I, Lechner K, Niessner H, Schmidt P, Balzar E, Mannhalter C. Pabinger-Fasching I, et al. Thromb Haemost. 1985 Feb 18;53(1):5-7. Thromb Haemost. 1985. PMID: 3838827

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page